Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer and Increase Awareness of Innovative Immuno-Oncology Research
• New survey shows lack of understanding of Immuno-Oncology and underscores need for greater education on cancer research
INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.
Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma
Pivotal Phase III studies (CheckMate -057 & -017) in both advanced non-squamous and squamous non-small cell lung cancer in which treatment with Opdivo demonstrated superior survival versus chemotherapy with docetaxel in previously-treated patients, to be disclosed
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tender Offer
Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities
Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Deutsche Bank Global Health Care Conference on Wednesday, May 6, 2015, in Boston. Giovanni Caforio, chief operating officer and CEO-designate, will answer questions about the company at 10:40 a.m. EDT.
Page 1 of 72